Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Reviva Pharmaceuticals Holdings Inc.

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.